Abstract
The development of antiangiogenic compounds for the treatment of cancer has indicated a need for new clinical tools to evaluate their efficacy, to assess the optimal dose with minimal side-effects and to early select patients who might benefit from antiangiogenic therapies. The use of so-called surrogate biomarkers of angiogenesis and antiangiogenic drug activity in the clinic does not yet belong to the standard of care. Most research has been dedicated towards introduction and refining of imaging techniques, the detection of circulating angiogenic factors and/or related molecules, and characterization and measurement of circulating endothelial cells and early progenitor cells. This chapter will discuss the various possibilities and their limitations illustrated with clinical data on antiangiogenic therapies in cancer patients.
Keywords: Surrogate Marker, Antiangiogenic Therapies, Efficasy, Limitation, Cancer Patient
Related Journals
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms
Current Technologies To Increase The Transdermal Delivery Of Drugs